公开(公告)号：US20210085667A1

公开(公告)日：2021-03-25

申请号：US17112097

申请日：2020-12-04

Applicant: RaQualia Pharma Inc. ,  Asahi Kasei Pharma Corporation

Inventor： Hirohide NOGUCHI ,  Yoshimasa ARANO ,  Kazuo ANDO ,  Kazuki TOYOSHIMA ,  Toshihiko SONE ,  Koki MATSUBARA

IPC: A61K31/47 ,  C07D215/06

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

公开(公告)号：US20170002016A1

公开(公告)日：2017-01-05

申请号：US15125615

申请日：2015-03-16

Applicant: RaQualia Pharma Inc.

Inventor： Yuji SHISHIDO ,  Masashi OHMI ,  Kazuo ANDO

IPC: C07D491/056 ,  A61K31/422 ,  A61K31/423 ,  C07D413/06 ,  C07D403/06 ,  A61K31/4184 ,  C07D403/14 ,  A61K31/497 ,  C07D401/14 ,  A61K31/4439 ,  C07D417/14 ,  A61K31/427 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/4545 ,  C07D417/06 ,  C07D235/02 ,  C07D403/10 ,  C07D471/04 ,  C07D401/12 ,  C07D403/12 ,  A61K31/506 ,  A61K31/501 ,  A61K31/444 ,  A61K31/517 ,  A61K31/502 ,  A61K31/437 ,  A61K31/519 ,  C07D487/04 ,  C07D409/10 ,  A61K31/498 ,  C07D491/048 ,  A61K31/4355 ,  A61K31/4985 ,  A61K31/5025 ,  C07D413/10 ,  C07D263/52 ,  C07D405/14 ,  A61K31/538 ,  C07D413/14

CPC classification number: C07D491/056 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/427 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/538 ,  C07D235/02 ,  C07D235/06 ,  C07D263/52 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/10 ,  C07D409/14 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/06 ,  C07D417/10 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048

Abstract: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

Abstract translation: 本发明涉及式（I）的azaspiro衍生物或其药学上可接受的盐或其前药，其制备方法，含有它们的药物组合物及其用于治疗通过TRPM8受体介导的各种病症的用途。

公开(公告)号：US20180339993A1

公开(公告)日：2018-11-29

申请号：US16050514

申请日：2018-07-31

Applicant: RaQualia Pharma Inc.

Inventor： Yuji SHISHIDO ,  Masashi OHMI ,  Kazuo ANDO

IPC: C07D491/056 ,  A61K31/538 ,  C07D235/06 ,  A61K31/423 ,  A61K31/4355 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  C07D413/10 ,  C07D235/02 ,  A61K31/517 ,  A61K31/435 ,  A61K31/422 ,  A61K31/4178 ,  C07D491/048 ,  C07D263/52 ,  C07D487/04 ,  C07D471/04 ,  C07D417/14 ,  C07D417/10 ,  C07D417/06 ,  C07D413/06 ,  C07D409/14 ,  C07D409/10 ,  C07D403/14 ,  C07D403/10 ,  C07D403/06 ,  C07D401/12 ,  A61K31/437 ,  A61K31/427 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  A61K31/4184

Abstract: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor,

公开(公告)号：US20240018103A1

公开(公告)日：2024-01-18

申请号：US18028062

申请日：2021-09-30

Applicant: RaQualia Pharma Inc.

Inventor： Kazuo ANDO ,  Masashi OHMI ,  Ryohei MAGARA

IPC: C07D209/38

CPC classification number: C07D209/38

Abstract: The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR2 is involved.

公开(公告)号：US20210078975A1

公开(公告)日：2021-03-18

申请号：US17046196

申请日：2019-04-09

Applicant: RaQualia Pharma Inc. ,  National University Corporation Tokai National Higher Education and Research System

Inventor： Masashi OHMI ,  Takeshi MATSUSHITA ,  Kazuo ANDO ,  Ryuichi YAMAGUCHI ,  Yutaka FUKUMOTO ,  Ryohei MAGARA ,  Tatsuya YAMAGISHI ,  Mikito TAKEFUJI

IPC: C07D401/14 ,  C07D471/04 ,  C07D413/14 ,  C07D417/14 ,  C07D405/14 ,  A61P9/00

Abstract: The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.

公开(公告)号：US20230339934A1

公开(公告)日：2023-10-26

申请号：US17921203

申请日：2021-04-30

Applicant: RaQualia Pharma Inc.

Inventor： Yuji SHISHIDO ,  Tadashi INOUE ,  Tatsuya YAMAGISHI ,  Kazuo ANDO ,  Yutaka FUKUMOTO ,  Ryohei MAGARA

IPC: C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: This invention relates to pyrimidin-4(3H)-one derivatives that act as modulators of the TRPV4 receptor. The present invention also relates to processes for the preparation of novel pyrimidin-4(3H)-one derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain, and urological diseases or disorders.

公开(公告)号：US20230149382A1

公开(公告)日：2023-05-18

申请号：US17871423

申请日：2022-07-22

Applicant: RaQualia Pharma Inc. ,  Asahi Kasei Pharma Corporation

Inventor： Hirohide NOGUCHI ,  Yoshimasa ARANO ,  Kazuo ANDO ,  Kazuki TOYOSHIMA ,  Toshihiko SONE ,  Koki MATSUBARA

IPC: A61K31/47 ,  C07D215/06

CPC classification number: A61K31/47 ,  C07D215/06

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.